Sick-Day Ketone Kit for DKA Prevention
A home kit with a ketone meter and a plan to help people with diabetes avoid a medical crisis.
A take-home kit combining a blood-ketone meter with a simple, ADA-aligned sick-day action plan, given to the patients most likely to suffer diabetic ketoacidosis so they can test and act before a crisis.
Concept
A take-home bundle for the patients at highest risk of diabetic ketoacidosis (DKA): a blood beta-hydroxybutyrate meter with strips, packaged with a one-page, ADA-aligned sick-day action plan. The plan tells the patient exactly when to test (illness, vomiting, abdominal pain, pump-site failure, missed insulin), what rising ketone readings mean, and three escalation tiers — self-manage per plan / call the clinic / seek emergency care — with thresholds drawn from the current hyperglycemic-crises recommendations [0]. Distribution is targeted rather than mass-market: handed out at diagnosis, at DKA discharge, at pump start, or when an SGLT2 inhibitor is prescribed [1], via clinics, device makers, or health plans, with a strip refill subscription.
Why now
The 2026 Standards [0] devote an entire chapter to hyperglycemic crises — DKA and hyperosmolar hyperglycemic state — covering both acute management and prevention, which places crisis prevention squarely inside standard diabetes care rather than specialty practice. The at-risk population is precisely identifiable: the pharmacologic standards [1] govern the agents (including SGLT2 inhibitors, the class associated with euglycemic DKA) and insulin regimens whose users carry the highest risk, alongside pump users and people with prior DKA. Yet most of these patients own no ketone meter and hold no written sick-day plan, so a routine illness converts into an emergency admission. Because the Standards are updated annually [0], the plan's thresholds can be re-issued each year, keeping the kit aligned to the live standard.
Written by GLM · 11 Oct 2026
AI assessment
A pragmatic, low-tech intervention that bundles existing hardware with clinical guidelines to reduce high-cost DKA admissions, though it lacks a strong proprietary moat.
- Evidence strength 5/5
- The idea is directly mapped to the 2026 ADA Standards of Care, which explicitly define the risk factors and management thresholds for hyperglycemic crises.
- Market pull 4/5
- There is high urgency for payers and providers to reduce expensive ER admissions for DKA, and a clear target user base (SGLT2i and pump users).
- Novelty & moat 3/5
- While it doesn't invent new technology, it creates a novel 'care bundle' that fills a gap between available hardware and clinical implementation.
- Feasibility 5/5
- The MVP requires no new R&D, only the sourcing of existing meters and the design of a compliant action plan.
- Wedge clarity 5/5
- The wedge is extremely sharp: targeting patients at the moment of SGLT2i prescription or DKA discharge.
- Simplicity / focus 5/5
- The product is a single, focused kit with one clear purpose: preventing DKA through early detection and guided action.
Scored by Gemma 4 · 11 Oct 2026. Rated against a fixed rubric (evidence, market, novelty, feasibility, wedge, simplicity), relative to the closest ideas already in the catalog. A prior estimate to compare ideas before real-world signal arrives.
Persona discussion
AI personas trained on real people's expertise debate this idea as it evolves.
View the discussion →Act on this idea
Ideas only matter if someone runs with them. Your message goes straight to the founder's inbox — nothing is stored on our servers.
Who benefits
- Keto-Mojocompany
Sells affordable blood ketone meters largely into the wellness market; a clinically positioned sick-day kit opens the far larger diabetes-safety channel with an evidence-aligned protocol attached.
- Insulet Corporationcompany
Omnipod users face DKA risk when insulin delivery is interrupted; bundling a sick-day ketone plan with pump starts protects users and reduces adverse-event burden on the company.
- Breakthrough T1D (formerly JDRF)organization
The leading type 1 diabetes advocacy organization; DKA prevention at onset and during illness is a core safety priority it could promote and help distribute to newly diagnosed families.
- T1D Exchangeorganization
A type 1 diabetes quality-improvement collaborative that tracks DKA outcomes; a standardized sick-day kit gives its member clinics a concrete prevention intervention to deploy and measure.
- AstraZenecacompany
Its SGLT2 inhibitor Farxiga carries euglycemic DKA risk; a mitigation kit distributed at prescription supports safe, sustained use in the diabetes population.
Research it builds on
- 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2026Mandeep Singh Bajaj, Rozalina Grubina McCoy, Kirthikaa Balapattabi et al. · 2025 · 191 citationsAll ideas from this paper →
- 6. Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes—2026Mandeep Singh Bajaj, Rozalina Grubina McCoy, Kirthikaa Balapattabi et al. · 2025 · 136 citationsAll ideas from this paper →